Trials / Completed
CompletedNCT04291391
The Alberta NutrIMM Study - Nutrition and Immunity
The Alberta NutrIMM (Nutrition and Immune Function) Study: Establishing the Importance of Diet and Insulin Resistance in Modulating Immune Function in Obesity
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the effect of body weight, diet, and high blood sugar levels, under controlled feeding conditions, on immune function in individuals with and without obesity. This study will be a non-randomized, four-arm parallel group, clinical trial under controlled feeding conditions (4-week nutritional intervention using a North American-type diet). A sample size of n=128 participants will be allocated into one of the following groups: * Individuals without obesity and normoglycemia (NG) (Lean-NG) * Individuals with obesity and normoglycemia (Obese-NG) * Individuals with obesity and glucose intolerance (GI) (Obese-GI) * Individuals with obesity and type 2 diabetes (T2D) (Obese-T2D) The following outcomes will be analyzed: * Immune cell function (ex-vivo cytokine production after stimulation with mitogen and T cell proliferation); * Immune cell phenotypes; * Systemic inflammation (C-reactive protein and plasma cytokines); * Glucose, insulin, glycated hemoglobin (HbA1c), and lipids; * Fatty acids and phospholipds composition in plasma and red blood cells membrane.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | North American-type diet | All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein) |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2023-05-16
- Completion
- 2023-12-01
- First posted
- 2020-03-02
- Last updated
- 2024-02-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04291391. Inclusion in this directory is not an endorsement.